EMD Serono leverages our synergistic portfolio in three key areas:
Explore our pipeline to see our curiosity in action.DOWNLOAD PDF
Our curiosity drives us to transform the standard of care for challenging cancers.
How do MET alterations drive oncogenesis in non-small cell lung cancer (NSCLC)? How do these alterations arise, and how do they impact patient prognosis? If you have patients with MET alterations, visit our website to learn more about testing options and additional information that can help inform treatment decisions for your patients with NSCLC.VISIT WEBSITE
Is the DNA damage response pathway a viable target for cancer therapy? This video discusses the key protein kinases implicated in DDR pathways and the potential implications of inhibition of these pathways in cancer.WATCH VIDEO
DDR, DNA damage response; MET, mesenchymal epithelial transition factor.